Alexion Pharmaceuticals ALXN shares are trading higher on Tuesday, on a report that Elliott Advisors sent a letter to the company seeking an immediate expiration of sales.
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. The company is known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.
Alexion Pharmaceuticals shares traded up 2.9% at $104.28 at time of publication. The stock has a 52-week high of $134.84 and a 52-week low of $72.67.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
